Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Maxcyte (MXCT) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to 191.71%.

  • Maxcyte's EBITDA Margin fell 326400.0% to 191.71% in Q3 2025 from the same period last year, while for Sep 2025 it was 149.41%, marking a year-over-year decrease of 523800.0%. This contributed to the annual value of 132.54% for FY2024, which is 155600.0% down from last year.
  • Maxcyte's EBITDA Margin amounted to 191.71% in Q3 2025, which was down 326400.0% from 154.44% recorded in Q2 2025.
  • Maxcyte's 5-year EBITDA Margin high stood at 24.09% for Q3 2021, and its period low was 191.71% during Q3 2025.
  • Moreover, its 5-year median value for EBITDA Margin was 104.39% (2024), whereas its average is 105.03%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first skyrocketed by 622300bps in 2022, then tumbled by -1177700bps in 2023.
  • Over the past 5 years, Maxcyte's EBITDA Margin (Quarter) stood at 48.81% in 2021, then decreased by -11bps to 54.34% in 2022, then grew by 5bps to 51.68% in 2023, then plummeted by -187bps to 148.41% in 2024, then fell by -29bps to 191.71% in 2025.
  • Its EBITDA Margin stands at 191.71% for Q3 2025, versus 154.44% for Q2 2025 and 118.33% for Q1 2025.